Medizinische Universitaet Innsbruck

The research unit of Medizinische Universitaet Innsbruck advances mental health science, focusing on innovative therapies for severe psychiatric conditions.

• Schizophrenia
• Bipolar disorder
• Major depressive disorder
• Cognitive impairment in schizophrenia
• Early psychosis
• Treatment‑resistant depression

Current trials assess novel antipsychotics and cognitive‑enhancing agents to improve functional recovery and quality of life.

Investigations target disorders of the central and peripheral nervous system, seeking disease‑modifying strategies for neurodegenerative and neuroinflammatory illnesses.

• Alzheimer’s disease
• Parkinson’s disease
• Multiple sclerosis
• Huntington’s disease
• Amyotrophic lateral sclerosis
• Progressive supranuclear palsy

Studies evaluate biomarkers and emerging biologics to slow progression and preserve neurological function.

The site conducts research on cardiovascular health, aiming to reduce morbidity through novel therapeutic and diagnostic approaches.

• Atherosclerotic cardiovascular disease
• Hypertension
• Heart failure with preserved ejection fraction
• Transthyretin amyloid cardiomyopathy
• Peripheral arterial disease
• Acute coronary syndrome

Projects include precision‑medicine trials of antiplatelet regimens and gene‑based risk stratification tools.

Researchers explore immune‑mediated disorders to develop targeted interventions that restore immune balance.

• Systemic lupus erythematosus
• Rheumatoid arthritis
• Sjögren’s syndrome
• Vasculitis (ANCA‑associated)
• Immunoglobulin A nephropathy
• Hypereosinophilic syndrome

Clinical programs test complement inhibitors, cytokine blockers, and novel small molecules for disease control.

The department participates in cutting‑edge cancer research, focusing on targeted and immunotherapies across solid and hematologic malignancies.

• Breast cancer (HR+/HER2‑, HER2+)
• Non‑small cell lung cancer
• Ovarian and fallopian tube cancer
• Multiple myeloma
• Lymphomas (follicular, marginal zone, DLBCL)
• Metastatic prostate cancer

Trials evaluate antibody‑drug conjugates, checkpoint inhibitors, and combination regimens to improve survival outcomes.

Studies address lung and airway disorders, seeking better management of chronic and acute respiratory conditions.

• Chronic obstructive pulmonary disease
• Asthma
• Pulmonary arterial hypertension
• Interstitial lung disease associated with hypertension
• Small cell lung cancer
• Bronchiectasis

Research includes inhaled therapies, novel vasodilators, and biomarker‑driven patient stratification.

The team investigates gastrointestinal disorders, aiming to enhance diagnostic precision and therapeutic effectiveness.

• Crohn’s disease
• Ulcerative colitis
• Celiac disease
• Chronic hepatitis D infection
• Alcohol‑associated hepatitis
• Non‑alcoholic steatohepatitis (NASH)

Ongoing work evaluates biologics, small‑molecule inhibitors, and lifestyle interventions for disease remission.

Research focuses on renal and urogenital diseases, targeting improved outcomes for chronic and acute kidney conditions.

• Autosomal dominant polycystic kidney disease
• IgA nephropathy
• Diabetic kidney disease
• Delayed graft function after transplantation
• Acute kidney injury related to contrast media
• Female urogenital disorders

Trials assess vasopressin‑2 receptor antagonists, contrast‑sparing strategies, and novel immunosuppressive protocols.